Presentation is loading. Please wait.

Presentation is loading. Please wait.

Multiple Sclerosis: An Overview for Pharmacists. What does MS look like? Julia—a 35yo white married mother of 3 who is exhausted all the time and can’t.

Similar presentations

Presentation on theme: "Multiple Sclerosis: An Overview for Pharmacists. What does MS look like? Julia—a 35yo white married mother of 3 who is exhausted all the time and can’t."— Presentation transcript:

1 Multiple Sclerosis: An Overview for Pharmacists

2 What does MS look like? Julia—a 35yo white married mother of 3 who is exhausted all the time and can’t drive because of vision problems and numbness in her feet Jackson—a 25yo African-American man who stopped working because he can’t control his bladder or remember what he read in the morning paper Maria—a 10yo Hispanic girl who falls down a lot and whose parents just told her she has MS Loretta—a 47yo white single woman who moved into a nursing home because she can no longer care for herself

3 What else does MS look like? Sam—a 45yo divorced white man who has looked and felt fine since he was diagnosed seven years ago Karen—a 24yo single white woman who is severely depressed and worried about losing her job because of her diagnosis of MS Sandra—a 30yo single mother of two who experiences severe burning pain in her legs and feet Richard—who was found on autopsy at age 76 to have MS but never knew it Jeannette—whose tremors are so severe that she cannot feed herself

4 1396: Earliest Recorded Case of MS

5 From Sister Lidwina to the present… 1868—Jean-Martin Charcot describes the disease and finds MS plaques (scars) on autopsy. 1878—Louis Ranvier describes the myelin sheath (the primary target of MS in the central nervous system). “Multiple sclerosis is often one of the most difficult problems in clinical medicine.” (Charcot, 1894) “When more is known of the causes and…pathology of the disease… more rational methods may brighten the therapeutic prospect.” (Gowers, 1898) 1981—1 st MRI image of MS is published.

6 From Sister Lidwina to the present, cont’d 1993—The first disease-modifying agent for MS— Betaseron—is approved in the U.S. 1998—Bruce Trapp confirms that the nerve fibers themselves are irreversibly damaged early in the disease course (probably accounting for the permanent disability that can occur). 2009—Today, there are seven medications approved in the U.S. for the treatment of MS and more in the pipeline. Today there are 400,000 people with MS in the U.S. and 2.5 million worldwide.

7 What MS Is: MS is thought to be a disease of the immune system— perhaps autoimmune. The immune system attacks the myelin coating around the nerves in the central nervous system (CNS—brain, spinal cord, and optic nerves) and the nerve fibers themselves. Its name comes from the scarring caused by inflammatory attacks at multiple sites in the central nervous system.

8 What MS Is Not: MS is not:  Contagious  Directly inherited  Always severely disabling  Fatal—except in fairly rare instances Being diagnosed with MS is not a reason to:  Stop working  Stop doing things that one enjoys  Not have children

9 What Causes MS? Genetic Predisposition Environmental Trigger Immune Attack Loss of myelin & nerve fiber

10 What happens in MS?...cross the blood-brain barrier… …launch attack on myelin & nerve fibers... “Activated” T cells... …to obstruct nerve signals myelinated nerve fiber

11 What happens to the myelin and nerve fibers?

12 What are possible symptoms?  Cognitive difficulties (memory, attention, processing)  Pain (neurogenic)  Heat sensitivity  Spasticity  Gait, balance, and coordination problems  Speech/swallowing problems  Tremor  Fatigue (most common)  Decreased visual acuity, diplopia  Bladder and/or bowel dysfunction  Sexual dysfunction  Paresthesias (tingling, (numbness, burning)  Emotional disturbances (depression, mood swings)  MS symptoms vary between individuals and are unpredictable

13 How is MS diagnosed? MS is a clinical diagnosis:  Signs and symptoms  Medical history  Laboratory tests Requires dissemination in time and space:  Space: Evidence of scarring (plaques) in at least two separate areas of the CNS (space)  Time: Evidence that the plaques occurred at different points in time There must be no other explanation

14 What tests may be used to help confirm the diagnosis? Magnetic resonance imaging (MRI) Visual evoked potentials (VEP) Lumbar puncture

15 What is a clinically-isolated syndrome (CIS)? First neurologic episode caused by demyelination in the CNS May be monofocal or multifocal May or may not go on to become MS  CIS accompanied by MS-like lesions on MRI is more likely to become MS than CIS without lesions on MRI Interferon medications delay second episode  Avonex, Betaseron, Extavia, Copaxone approved for this use  Rebif has demonstrated its effectiveness

16 Who gets MS? Usually diagnosed between 20 and 50  Occasionally diagnosed in young children and older adults More common in women than men (2-3:1) Most common in those of Northern European ancestry  More common in Caucasians than Hispanics or African Americans; rare among Asians More common in temperate areas (further from the equator)

17 What is the genetic factor? The risk of getting MS is approximately:  1/750 for the general population (0.1%)  1/40 for person with a close relative with MS (3%)  1/4 for an identical twin (25%) 20% of people with MS have a blood relative with MS The risk is higher in any family in which there are several family members with the disease (aka multiplex families)

18 What is the prognosis? One hallmark of MS is its unpredictability.  Approximately 1/3 will have a very mild course  Approximately 1/3 will have a moderate course  Approximately 1/3 will become more disabled Certain characteristics predict a better outcome:  Female  Onset before age 35  Sensory symptoms  Monofocal rather than multifocal episodes  Complete recovery following a relapse

19 What are the different patterns (courses) of MS? Relapsing-Remitting MS (RRMS) Secondary Progressive MS (SPMS) Primary Progressive MS (PPMS) Progressive-Relapsing MS (PRMS)

20 Relapsing-Remitting MS Increasing disability time

21 Secondary-Progressive MS Increasing disability time

22 Primary-Progressive MS Increasing disability time

23 Progressive-Relapsing MS Increasing disability time

24 An Overview of Treatment Strategies

25 Who is on the MS “Treatment Team”? Neurologist Urologist Nurse Physiatrist Physical therapist Occupational therapist Speech/language pathologist Psychiatrist Psychotherapist Neuropsychologist Social worker/Care manager Pharmacist

26 What are the treatment strategies? Gone are the “Diagnose and Adios” days of MS care Management of MS falls into five general categories:  Treatment of relapses (aka exacerbations, flare-ups, attacks—that last at least 24 hours)  Symptom management  Disease modification  Rehabilitation (maintain/improve function)  Psychosocial support

27 How are relapses treated? Not all relapses require treatment  Mild, sensory sx are allowed to resolve on their own.  Sx that interfere with function (e.g., visual or walking problems) are usually treated 3-5 day course of IV methylprednisolone—with/without an oral taper of prednisone  High-dose oral steroids used by some neurologists Rehabilitation to restore/maintain function Psychosocial support

28 How is the disease course treated? Ten disease-modifying therapies are FDA-approved for relapsing forms of MS:  interferon beta-1a (Avonex® and Rebif®) [inj.]  interferon beta-1b (Betaseron® and Extavia®) [inj.]  glatiramer acetate (Copaxone®) [inj.]  fingolimod (Gilenya™) [oral]  teriflunomide (Aubagio®) [oral]  Dimethyl fumarate (Tecfidera™  natalizumab (Tysabri®) [inf]  mitoxantrone (Novantrone®) [inf]

29 What do the disease-modifying drugs do? All reduce attack frequency and severity, reduce scarring on MRI, and probably slow disease progression. These medications do not:  Cure the disease  Make people feel better  Alleviate symptoms

30 How important is early treatment? The Society’s National Medical Advisory Committee recommends that treatment be considered as soon as a dx of relapsing MS has been confirmed.  Irreversible damage to axons occurs even in the earliest stages of the illness.  Tx is most effective during early, inflammatory phase  Tx is least effective during later, neurodegenerative phase No treatment has been approved for primary-progressive MS. Approximately 60% of PwMS are on Tx

31 What factors affect treatment adherence? Patient readiness is key Factors affecting readiness include:  Lack of knowledge about MS  Denial of illness  Unrealistic expectations of treatment outcomes  Side effects  Cultural factors  Lack of support (medical team, family)  Distrust of medical community and/or prescription medications

32 Treatment Challenges in MS Research Current therapies—primarily anti-inflammatory Future therapies  Design selective therapies that target very specific components of the immune system  Utilize combination of strategies:  Anti-inflammatory  Neural repair  Neuroprotection

33 New Treatments on Horizon Enhancement of Existing Therapies Potential Therapies  Oral estrogens/testosterone laquinimod  Parenteral rituximab (Rituxan) alemtuzumab (Lemtrada) declizumab (Zenapax) dirucotide

34 Managing MS Symptoms Symptom management begins on Day 1 and continues throughout the disease course. Symptom management is an art. Virtually every medication used to treat MS symptoms is used off-label. Effective symptom management involves medication, rehabilitation strategies, emotional support—and good coordination of care.

35 Managing MS Fatigue > 80% of people with MS experience fatigue; many identify it as their most disabling Along with cognitive dysfunction, fatigue is the most common cause of early departure from the workforce MS fatigue is easily misunderstood by family members and employers as laziness or disinterest MS fatigue is multi-faceted

36 Managing MS Fatigue, cont’d Identify/address contributory factors  Disrupted sleep; muscle fatigue; disability-related fatigue; depression; medications Develop comprehensive treatment plan  Medications: amantadine; modafinil  Energy management: planning/prioritizing; mobility aids  Exercise regimen

37 Managing Bladder Dysfunction > 75% of people with MS will experience bladder problems. Bladder dysfunction is a major cause of morbidity, embarrassment, and social isolation.

38 Managing Bladder Dysfunction Storage dysfunction  Small, spastic bladder in which small quantity of urine triggers the urge to void  Sx include: urgency, frequency, incontinence, nocturia  Tx includes: anticiholinergic/antimuscarinic medication Emptying dysfunction  Bladder fails to empty  risk of UTI  Sx include: urgency, frequency, nocturia, incontinence Tx includes: ISC and anticholinergic/antimuscarinic medications

39 Managing Bowel Problems Experienced by 50% of people with MS  Constipation—most common “Diarrhea” (related to impaction)  Bowel incontinence—least common Managed best with regular bowel routine  Adequate fluid/fiber intake  Exercise  OTC products as needed  Anticholinergic medications added to manage incontinence

40 Managing Spasticity (increased muscle tone) Experienced by 40-60% of people with MS (more common in the lower extremities) Management strategies:  Stretching  Oral medication (baclofen, tizanidine, clonazapam, gabapentin, cyproheptidine, dantrolene, dopaminergic agonists  Baclofen pump  Botox injections; nerve blocks; surgery Some spasticity is useful to counteract weakness

41 Managing Primary Sexual Dysfunction 40-80% of men and women with MS  Reduced libido (behavioral/environmental strategies)  Sensory disturbances (anticonvulsant medications)  Anorgasmia (body-mapping exercises) Women  Reduced lubrication (gels) Men  Erectile dysfunction (pharmacotherapy; implants)

42 Managing Secondary/Tertiary Sexual Dysfunction Secondary dysfunction (other contributory factors)  Managing MS symptoms that interfere with sexual activity/pleasure (fatigue, spasticity, etc.)  Managing medications to promote sexual comfort and responsiveness (anticholinergics; antidepressants, fatigue and spasticity meds) Tertiary dysfunction (feeling; attitudes) Education; counseling

43 Managing Cognitive Dysfunction Occurs in 50-60% of people with MS Ranges from relatively mild to quite severe Correlates with number of lesions and lesion area on MRI, as well as brain atrophy Can occur at any time but is more common later in the disease Can occur with any disease course, but is slightly more likely in progressive MS. Being in an exacerbation is a risk factor for cognitive dysfunction. Most common problems: memory; attention/concentration; information processing Treatments:  Disease-modifying therapy to prevent relapses  Cognitive rehabilitation: primarily compensatory

44 Managing Depression >50% of people with MS will experience a major depressive episode. Suicide in MS is 7x higher than in the general population.  Greatest risk factor for suicide in MS is depression. Depression is under-recognized, under- diagnosed and under-treated in MS Recommended tx = psychotherapy + medication + exercise

45 Managing Pain 75% of people with MS experience pain Neuropathic (central) pain  Paroxysmal pain (trigeminal neuralgia; headache) Anticonvulsants  Continuous pain (dysesthesias) Tricicyclics; anticonvulsants Nociceptive (secondary) pain  Musculskeletal pain  Physical therapy; NSAIDs  Spasticity—As described previously

46 Managing Ataxia/Tremor Incidence is unknown Potentially severely disabling No effective treatments at this time  Medications that may be tried: propranolol; primidone; acetazolamide; buspirone; clonazepam  Occupational therapy Weighting; assistive devices  Thalamic surgery for tremor (generally poor results)

47 Serious Complications Urosepsis Aspiration pneumonia Pulmonary dysfunction Skin breakdown Untreated depression Osteoporosis

48 What can people do to feel their best? Balance activity with rest. Talk with their doctor about the right type/amount of exercise for them. Eat a balanced low-fat, high-fiber diet. Avoid heat if they are heat-sensitive. Drink plenty of fluids to maintain bladder health and avoid constipation. Follow the standard preventive health measures recommended for their age group

49 What else can people do to feel their best? Reach out to their support system; no one needs to be alone in coping with MS. Stay connected with others; avoid isolation. Become an educated consumer. Make thoughtful decisions regarding:  Disclosure  Choice of physician  Employment choices  Financial planning Be aware of common emotional reactions.

50 The Allure of CAM

51 Understanding CAM’s Allure MS treatments are only partially effective. Personal testamonials are extremely powerful. Many people believe “Safe…natural…healthy…effective…” and distrust the effects of mainstream medicine. It feels good to “take charge” of a chronic, unpredictable disease.

52 The Use of Complementary and Alternative Medicine (CAM) in MS Used by 50-88% of people with MS, generally in conjunction with conventional treatments Practitioners optimize the placebo effect Recommendations to patients from Allen Bowling, MD, PhD  Consider conventional medicine first  Learn about effectiveness, safety, cost  Discuss it with your physician  Use caution (“buyer beware”)  Remember: MS involves excessive immune activity; no need to “boost” immune system” Bowling AC. Complementary and Alternative Medicine in Multiple Sclerosis (2nd ed.). New York: Demos Medical Publishing, 2007

53 Possibly Beneficial CAM Interventions Diet low in saturated fat and enriched in polyunsaturated fatty acids (may suppress immune system) Acupuncture: anxiety, bladder; depression; pain; sleep Massage: anxiety, pain, depression; pain; spasticity Meditation: anxiety, pain, depression, pain Exercise (T’ai chi; yoga): fatigue; anxiety, depression; weakness; walking Cooling: fatigue; spasticity; walking Biofeedback: anxiety; pain; sleep; bladder Bowling AC. Complementary and Alternative Medicine in Multiple Sclerosis (2 nd ed.). New York: Demos Medical Publishing, 2007

54 Dietary Supplements to be Avoided Alfalfa Ashwagandha Astragalus Cat’s claw Garlic Licorice Melatonin Oligomeric proanthocyanidins Pycnogenol Saw palmetto Selenium Stinging nettle Vitamin A Zinc Supplements that may stimulate the immune system: Bowling AC. Complementary and Alternative Medicine in Multiple Sclerosis (2nd ed.). New York: Demos Medical Publishing, 2007

55 So what do we know about MS? MS is a chronic, unpredictable disease The cause is still unknown MS affects each person differently; symptoms vary widely MS is not fatal, contagious, directly inherited, or always disabling Early diagnosis and treatment are important  Significant, irreversible damage can occur early on  Available treatments reduce the number of relapses and may slow progression Treatment includes: attack management, symptom management, disease modification, rehab, emotional support

56 NMSS Resources for Patients and Families 40+ chapters around the country Web site ( Access to information, referrals, support (1-800-344-4867) Educational programs (in-person, online) Support programs (self-help groups, peer and professional counseling, friendly visitors) Consultation (legal, employment, insurance, long-term care) Financial assistance

57 Society Resources for Professionals MS Clinical Care Network Website: Email:  Comprehensive MS library/literature search services  Clinical consultations with MS specialists  Professional publications  Professional education programs (medical, rehab, nursing, mental health)  Consultation on insurance and long-term care issues

Download ppt "Multiple Sclerosis: An Overview for Pharmacists. What does MS look like? Julia—a 35yo white married mother of 3 who is exhausted all the time and can’t."

Similar presentations

Ads by Google